Regenerative Medical Technology (RMTG) Interest Expenses (2017 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Interest Expenses of $2.2 million for Q1 2026, up 144.52% year-over-year from $895850.0 in Q1 2025, and up 9.11% quarter-over-quarter from $2.0 million in Q4 2025.
Regenerative Medical Technology (RMTG) Interest Expenses (2017 - 2026) Analysis & Trends
Regenerative Medical Technology's Interest Expenses history runs 10 years deep, the most recent figure standing at $2.2 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 144.52% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $8.7 million (up 86.73% YoY), while the FY2025 annual figure was $7.7 million, up 28.41% from the prior year.
- Interest Expenses for Q1 2026 stood at $2.2 million, up from $2.0 million in the prior quarter.
- The five-year high for Interest Expenses was $3.5 million in Q3 2025, with the low at -$4.9 million in Q4 2023.
- The 5-year median for Interest Expenses is $1.1 million (2022), against an average of $943690.4.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses sank 26988766.67% in 2023, then jumped 68504.68% in 2024.
- Regenerative Medical Technology's Interest Expenses stood at $18.0 in 2022, then tumbled by 26988766.67% to -$4.9 million in 2023, then soared by 120.99% to $1.0 million in 2024, then jumped by 96.88% to $2.0 million in 2025, then gained by 9.11% to $2.2 million in 2026.
- Business Quant data shows RMTG's Interest Expenses at $2.2 million in Q1 2026, $2.0 million in Q4 2025, and $3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn | 2.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.19 Mn |
| Mar 31, 2026 | 2.19 Mn |
| Dec 31, 2025 | 2.01 Mn |
| Dec 31, 2025 | 2.01 Mn |
| Sep 30, 2025 | 3.49 Mn |
| Sep 30, 2025 | 3.49 Mn |
| Jun 30, 2025 | 1.06 Mn |
| Jun 30, 2025 | 1.06 Mn |
| Mar 31, 2025 | 895,850.00 |
| Mar 31, 2025 | 895,850.00 |
| Dec 31, 2024 | 1.02 Mn |
| Dec 31, 2024 | 1.02 Mn |
| Sep 30, 2024 | 905,572.00 |
| Sep 30, 2024 | 905,572.00 |
| Jun 30, 2024 | 1.86 Mn |
| Jun 30, 2024 | 1.86 Mn |
| Mar 31, 2024 | 1.85 Mn |
| Mar 31, 2024 | 1.85 Mn |
| Dec 31, 2023 | -4.86 Mn |
| Dec 31, 2023 | -4.86 Mn |